TD Waterhouse Canada
CASI icon

TD Waterhouse Canada’s CASI Pharmaceuticals CASI Stock Holding History

TD Waterhouse Canada’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-300
Closed -$1.03K – 1926
2024
Q1 		$1.03K Buy
+300
New +$1.62K ﹤0.01% 1730

Other funds holding CASI

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HCM
Howland Capital Management Boston, Massachusetts $2.77B AUM 19.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TD Waterhouse Canada's CASI Position: Q2 2024 in Review

TD Waterhouse Canada sold out of CASI Pharmaceuticals (CASI) in Q2 2024, closing a stake of 300 shares — an estimated $1.03K sold.

TD Waterhouse Canada first reported a position in CASI in Q1 2024 and held it in 1 quarter. The position peaked at $1.03K in Q1 2024. 23 funds tracked by Wall St. Rank hold CASI as of Q2 2024.

  • TD Waterhouse Canada reported no remaining CASI Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • TD Waterhouse Canada sold 300 CASI Pharmaceuticals shares in Q2 2024, an estimated $1.03K.
  • TD Waterhouse Canada first reported a position in CASI Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • TD Waterhouse Canada's CASI Pharmaceuticals position peaked at $1.03K in Q1 2024.
  • 23 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q2 2024.

Based on TD Waterhouse Canada's 13F filing for Q2 2024, filed 2 Aug 2024.